MA37763B1 - Difluoro-hexahydro-cyclopentaoxazinyl and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors - Google Patents
Difluoro-hexahydro-cyclopentaoxazinyl and difluoro-hexahydro-benzooxazinyls as bace1 inhibitorsInfo
- Publication number
- MA37763B1 MA37763B1 MA37763A MA37763A MA37763B1 MA 37763 B1 MA37763 B1 MA 37763B1 MA 37763 A MA37763 A MA 37763A MA 37763 A MA37763 A MA 37763A MA 37763 B1 MA37763 B1 MA 37763B1
- Authority
- MA
- Morocco
- Prior art keywords
- hexahydro
- difluoro
- benzooxazinyls
- cyclopentaoxazinyl
- bace1 inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La présente invention concerne des difluorocyclopentaoxazinyles et des difluorobenzooxazinyles de formule (i), présentant une activité inhibitrice de bace1, leur préparation, des compositions pharmaceutiques les contenant et leur utilisation en tant que substances actives sur le plan thérapeutique. Les composés actifs de la présente invention sont utiles dans le traitement thérapeutique et/ou prophylactique de, par exemple, la maladie d'alzheimer.The present invention relates to difluorocyclopentaoxazinyls and difluorobenzooxazinyls of formula (i), having a bace1 inhibitory activity, their preparation, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and / or prophylactic treatment of, for example, Alzheimer's disease.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12173690 | 2012-06-26 | ||
| PCT/EP2013/063086 WO2014001228A1 (en) | 2012-06-26 | 2013-06-24 | Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA37763A1 MA37763A1 (en) | 2016-08-31 |
| MA37763B1 true MA37763B1 (en) | 2017-05-31 |
Family
ID=48672630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37763A MA37763B1 (en) | 2012-06-26 | 2013-06-24 | Difluoro-hexahydro-cyclopentaoxazinyl and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9181232B2 (en) |
| EP (1) | EP2864324B1 (en) |
| JP (1) | JP6251257B2 (en) |
| KR (1) | KR20150023450A (en) |
| CN (1) | CN104470915B (en) |
| AU (1) | AU2013283524B2 (en) |
| BR (1) | BR112014029742A2 (en) |
| CA (1) | CA2872181A1 (en) |
| CL (1) | CL2014003325A1 (en) |
| CO (1) | CO7151509A2 (en) |
| CR (1) | CR20140528A (en) |
| EA (1) | EA025273B1 (en) |
| HK (1) | HK1206344A1 (en) |
| IL (1) | IL236138A (en) |
| MA (1) | MA37763B1 (en) |
| MX (1) | MX2014014937A (en) |
| NZ (1) | NZ702253A (en) |
| PE (1) | PE20142450A1 (en) |
| PH (1) | PH12014502623B1 (en) |
| SG (1) | SG11201407576YA (en) |
| UA (1) | UA113309C2 (en) |
| WO (1) | WO2014001228A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ589590A (en) | 2008-06-13 | 2012-05-25 | Shionogi & Co | Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity |
| AU2010328975B2 (en) † | 2009-12-11 | 2015-01-22 | Shionogi & Co. Ltd. | Oxazine derivative |
| US9540359B2 (en) | 2012-10-24 | 2017-01-10 | Shionogi & Co., Ltd. | Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity |
| TW201446758A (en) | 2013-03-01 | 2014-12-16 | Amgen Inc | Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| KR20150124985A (en) | 2013-03-08 | 2015-11-06 | 암젠 인크 | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| TW201623295A (en) | 2014-04-11 | 2016-07-01 | 塩野義製藥股份有限公司 | Dihydrothiazine and dihydrooxazine derivatives having BACE1 inhibitory activity |
| CN106795147B (en) | 2014-08-08 | 2020-09-22 | 美国安进公司 | Cyclopropyl fused thiazine-2-amine compounds as beta-secretase inhibitors and methods of use |
| WO2016150785A1 (en) | 2015-03-20 | 2016-09-29 | F. Hoffmann-La Roche Ag | Bace1 inhibitors |
| US11629154B2 (en) | 2018-04-27 | 2023-04-18 | Shionogi & Co., Ltd. | Tetrahydropyranooxazine derivatives having selective BACE1 inhibitory activity |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8703785B2 (en) | 2008-10-22 | 2014-04-22 | Shionogi & Co., Ltd. | 2-aminopyrimidin-4-one and 2-aminopyridine derivatives both having BACE1-inhibiting activity |
| GB0912778D0 (en) * | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydro-oxazine derivatives |
| AU2010328975B2 (en) * | 2009-12-11 | 2015-01-22 | Shionogi & Co. Ltd. | Oxazine derivative |
| UA103272C2 (en) * | 2009-12-11 | 2013-09-25 | Ф. Хоффманн-Ля Рош Аг | 2-amino-5,5-difluoro-5,6-dihydro-4h-[1,3]oxazines as bace1 and/or bace2 inhibitors |
-
2013
- 2013-06-24 JP JP2015519008A patent/JP6251257B2/en not_active Expired - Fee Related
- 2013-06-24 BR BR112014029742A patent/BR112014029742A2/en not_active IP Right Cessation
- 2013-06-24 EA EA201590066A patent/EA025273B1/en not_active IP Right Cessation
- 2013-06-24 SG SG11201407576YA patent/SG11201407576YA/en unknown
- 2013-06-24 NZ NZ702253A patent/NZ702253A/en not_active IP Right Cessation
- 2013-06-24 AU AU2013283524A patent/AU2013283524B2/en not_active Expired - Fee Related
- 2013-06-24 EP EP13730887.0A patent/EP2864324B1/en not_active Not-in-force
- 2013-06-24 MX MX2014014937A patent/MX2014014937A/en unknown
- 2013-06-24 CN CN201380033783.7A patent/CN104470915B/en not_active Expired - Fee Related
- 2013-06-24 WO PCT/EP2013/063086 patent/WO2014001228A1/en active Application Filing
- 2013-06-24 PE PE2014002406A patent/PE20142450A1/en not_active Application Discontinuation
- 2013-06-24 CA CA2872181A patent/CA2872181A1/en not_active Abandoned
- 2013-06-24 UA UAA201500578A patent/UA113309C2/en unknown
- 2013-06-24 KR KR20147036016A patent/KR20150023450A/en not_active Application Discontinuation
- 2013-06-24 MA MA37763A patent/MA37763B1/en unknown
- 2013-06-24 US US14/406,289 patent/US9181232B2/en not_active Expired - Fee Related
-
2014
- 2014-11-18 CR CR20140528A patent/CR20140528A/en unknown
- 2014-11-24 PH PH12014502623A patent/PH12014502623B1/en unknown
- 2014-12-05 CL CL2014003325A patent/CL2014003325A1/en unknown
- 2014-12-08 IL IL236138A patent/IL236138A/en not_active IP Right Cessation
- 2014-12-10 CO CO14271199A patent/CO7151509A2/en unknown
-
2015
- 2015-07-21 HK HK15106931.2A patent/HK1206344A1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013283524B2 (en) | 2017-03-30 |
| CL2014003325A1 (en) | 2015-04-24 |
| WO2014001228A1 (en) | 2014-01-03 |
| EP2864324B1 (en) | 2018-03-28 |
| MA37763A1 (en) | 2016-08-31 |
| PH12014502623A1 (en) | 2015-01-21 |
| US9181232B2 (en) | 2015-11-10 |
| MX2014014937A (en) | 2015-03-09 |
| IL236138A0 (en) | 2015-02-01 |
| US20150133440A1 (en) | 2015-05-14 |
| EA201590066A1 (en) | 2015-04-30 |
| IL236138A (en) | 2016-10-31 |
| CR20140528A (en) | 2015-01-12 |
| CN104470915A (en) | 2015-03-25 |
| SG11201407576YA (en) | 2015-03-30 |
| CO7151509A2 (en) | 2014-12-29 |
| AU2013283524A1 (en) | 2014-11-13 |
| UA113309C2 (en) | 2017-01-10 |
| PH12014502623B1 (en) | 2015-01-21 |
| CA2872181A1 (en) | 2014-01-03 |
| HK1206344A1 (en) | 2016-01-08 |
| KR20150023450A (en) | 2015-03-05 |
| JP6251257B2 (en) | 2017-12-20 |
| CN104470915B (en) | 2019-07-26 |
| BR112014029742A2 (en) | 2017-06-27 |
| EP2864324A1 (en) | 2015-04-29 |
| NZ702253A (en) | 2016-06-24 |
| JP2015521640A (en) | 2015-07-30 |
| PE20142450A1 (en) | 2015-01-28 |
| EA025273B1 (en) | 2016-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA35193B1 (en) | Halogeno-1,3-alkyl oxazines as inhibitors of bace1 and / or bace2 | |
| MA35191B1 (en) | Spiro- [1,3] -oxazines and spiro- [1,4] -oxazepines as inhibitors of baec1 and / or bace2 | |
| MA37763A1 (en) | Difluoro-hexahydro-cyclopentaoxazinyl and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors | |
| MA35246B1 (en) | 1,3-oxazines as inhibitors of bace1 and / or bace2 | |
| MA38556A1 (en) | Inhibitors of bace1 | |
| MA37691B1 (en) | 5-amino [1,4] thiazines as bace1 inhibitors | |
| MA35748B1 (en) | Fluoromethyl-5,6-dihydro-4H- [1,3] oxazine | |
| MA35576B1 (en) | New compounds | |
| MA42295B1 (en) | Benzoxazepin oxazolidinone compounds and method for their use | |
| BR112015016315A2 (en) | fluoro- [1,3] oxazine as bace1 inhibitors | |
| MA38380A1 (en) | Quinazoline inhibitors of activation of mutant forms of epidermal growth receptor (EGFR) | |
| MA33239B1 (en) | 3h Imidazo - [4,5-c] pyridine-6-carboxamide as an anti-inflammatory | |
| MA35348B1 (en) | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as inhibitors of btk | |
| MA41179A (en) | PARG INHIBITOR COMPOUNDS | |
| MA39219A1 (en) | New lrrk2 Kinase Inhibitor Compounds Used to Treat Parkinson's, Alzheimer's and Amyotrophic Lateral Sclerosis | |
| MX2013007558A (en) | 1,4 oxazines as bace1 and/or bace2 inhibitors. | |
| MA34474B1 (en) | AGONISTS OF GPR40 | |
| MA33053B1 (en) | INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE (PARP) | |
| MA33467B1 (en) | Primary drugs include insulin-linking facilities | |
| MX2013007957A (en) | 1,4 oxazines as bace1 and/or bace2 inhibitors. | |
| MX2013008478A (en) | 1,4 thiazepines/sulfones as bace1 and/or bace2 inhibitors. | |
| MA35455B1 (en) | (wo2013045407) derivatives of estra-1,3,5 (10), 16-tetraene-3-carboxamide, process for their manufacture, pharmaceutical preparations containing these substances and their use in the manufacture of medicaments | |
| MA38260A1 (en) | Novel cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist activity and muscarinic m3 antagonist activity | |
| BR112017015474A2 (en) | bace1 inhibitors | |
| MA33979B1 (en) | Piperazine as antimalarial agents |